Trends in Medicare Part D spending on topical steroids from 2012 to 2021: Increasing costs of generic topical steroids and potential savings
Journal of the American Academy of Dermatology · 2025
DOI: 10.1016/j.jaad.2025.02.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2025. Verfasst von Sophia Ly und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arka…. Hauptthemen laut MEDLINE: Drugs, Generic, Medicare Part D, Cost Savings, Drug Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Increasing prescription drug costs are a major concern in health care. The literature lacks an up-to-date assessment of US expenditures on topical steroids, one of the most prescribed medications in dermatology. OBJECTIVE: To characterize trends in Medicare spending and costs per unit of topical steroids and to model potential savings from substitution of the cheapest steroid within each potency class. METHODS: This is a retrospective analysis of Medicare Part D Public Use Files, which provides prescription drug expenditure data between 2012 and 2021. RESULTS: Between 2012 and 2021, Medicare Part D spent $5.7 billion on topical steroids, with generics accounting for 98.3%. While there has been a steady decline since 2015, total annual spending has overall increased by 35.6%, from $322.2 million in 2012 to $437 million in 2021. Inflation-adjusted costs per unit increased for most generic topical steroids, while the rate of change declined with increasing market competition. Medicare had potential savings of $2.4 billion if prescriptions were substituted for the cheapest steroid within each potency class. LIMITATIONS: The data set represented only 70% to 77% of beneficiaries with Part D plans, excluded manufacturer rebates, and aggregated all drug strengths. We also excluded drugs with proprietary vehicles. CONCLUSION: Medicare expenditures on topical steroids have increased in the past decade, primarily driven by rising generic drug costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas; Lankenau Medical Center, Wynnewood, Pennsylvania.
- Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Chobanian & Avedisian School of Medicine, Boston University, Boston, Massachusetts; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Kaiser Permanente, San Francisco, California.
- Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: amostaghimi@bwh.harvard.edu.
Zitieren
APA
Ly, S., Manjaly, P., Kamal, K., & Mostaghimi, A. (2025). Trends in Medicare Part D spending on topical steroids from 2012 to 2021: Increasing costs of generic topical steroids and potential savings. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.02.025
Vancouver
Ly S, Manjaly P, Kamal K, Mostaghimi A. Trends in Medicare Part D spending on topical steroids from 2012 to 2021: Increasing costs of generic topical steroids and potential savings. Journal of the American Academy of Dermatology. 2025. doi:10.1016/j.jaad.2025.02.025
BibTeX
@article{Ly2025,
author = {Ly, Sophia and Manjaly, Priya and Kamal, Kanika and Mostaghimi, Arash},
title = {Trends in Medicare Part D spending on topical steroids from 2012 to 2021: Increasing costs of generic topical steroids and potential savings},
journal = {Journal of the American Academy of Dermatology},
year = {2025},
doi = {10.1016/j.jaad.2025.02.025}
}
EUVIMED